Related Experiment Videos
Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats
K Teraoka1, M Hirano, K Yamaguchi
1Tokyo Medical College, 2nd Department of Internal Medicine, Kunihiko Teraoka, 6-7-1 Nishishinjuku, Shinjuku-ku, 160-0023, Tokyo, Japan. teraoka@tokyo-med.ac.jp
European Journal of Heart Failure
|December 13, 2000
Summary
Adriamycin (doxorubicin) cancer treatment causes cardiotoxicity. This study developed a method to induce cardiomyopathy in rats, minimizing peritonitis, and assessed cardiac function and mortality.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Cardiotoxicity is a significant limitation of adriamycin (doxorubicin) chemotherapy.
- Developing reliable models to study adriamycin-induced cardiotoxicity is crucial for patient safety.
Purpose of the Study:
- To establish an adriamycin-induced cardiomyopathy rat model using a novel administration method.
- To evaluate cardiac function and mortality in this model, minimizing peritonitis complications.
Main Methods:
- Sixty male Wistar rats received 15 intraperitoneal injections of adriamycin (1 mg/kg) over 3 weeks.
- Fifteen control rats received saline injections.
- Cardiac function and volume were assessed via echocardiography at 4, 8, and 12 weeks; mortality was monitored for 12 weeks.
Main Results:
- Adriamycin-treated rats exhibited a 35.8% cumulative mortality rate compared to 0% in controls.
- Significant increases in left ventricular diameters (systolic and diastolic) and a significant decrease in fractional shortening were observed in adriamycin-treated rats.
- The administration method successfully induced cardiomyopathy while mitigating peritonitis.
Conclusions:
- The novel adriamycin administration method effectively induces cardiomyopathy in rats.
- This model is suitable for investigating adriamycin's cardiac effects, avoiding peritonitis interference.
- This approach aids in understanding and potentially mitigating chemotherapy-related heart damage.